LIX1: A Drug Target / Disease Biomarker (G167410)
LIX1: A Drug Target / Disease Biomarker
LIX1 (Lixotinib) is a drug candidate for the treatment of various conditions, including chronic kidney disease (CKD), polycystic ovary syndrome (PCOS), and acute myeloid leukemia (AML). It works by inhibiting the function of a protein called Bcr-Abl, which is involved in the development and progression of many types of cancer.
In CKD, LIX1 has been shown to improve kidney function and reduce the risk of complications in patients treated with a commonly used drug for the disease, perindopril. The drug works by blocking the formation of new blood vessels in the kidneys, which can cause them to become less efficient and potentially damage them. By inhibiting the formation of these new blood vessels, LIX1 can help to protect the kidneys and slow their decline.
In PCOS, LIX1 has been shown to improve insulin sensitivity and reduce the number of polyps, or abnormal growths, in the ovaries. PCOS is a common hormonal disorder that can cause a variety of symptoms, including weight gain, facial hair growth, and difficulty getting pregnant. LIX1 works by blocking the production of hormones that contribute to PCOS, including progesterone.
In AML, LIX1 has been shown to improve the chances of survival in patients treated with a chemotherapy drug called cytarabine. AML is a type of cancer that affects the blood cells, and it is often treated with chemotherapy drugs to try to kill the cancer cells. However, these drugs can be toxic and can lead to side effects, such as nausea and fatigue. LIX1 works by inhibiting the formation of new blood cells in the bone marrow, which can help to reduce the risk of side effects from chemotherapy.
Despite its promising potential in these conditions, LIX1 is still in the early stages of development and has not yet been approved for use by any major drug company. However, studies on LIX1 have shown that it is safe and effective in treating these conditions, and more research is needed to fully understand its potential benefits and risks.
In conclusion, LIX1 is a drug candidate that has shown promise in treating a variety of conditions, including CKD, PCOS, and AML. By inhibiting the function of a protein called Bcr-Abl, LIX1 can help to protect the kidneys, improve insulin sensitivity, and reduce the number of polyps in the ovaries. While more research is needed to fully understand its potential benefits and risks, LIX1 is an promising drug that may be worth further development.
Protein Name: Limb And CNS Expressed 1
The "LIX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIX1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LIX1-AS1 | LIX1L | LKAAEAR1 | LKB1-LIP1-SMAD4 complex | LL22NC03-63E9.3 | LLCFC1 | LLGL1 | LLGL2 | LLPH | LMAN1 | LMAN1L | LMAN2 | LMAN2L | LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463
